XM does not provide services to residents of the United States of America.
B
B

BayerAG

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

German cabinet approves restricted use of herbicide glyphosate

German cabinet approves restricted use of herbicide glyphosate BERLIN, April 24 (Reuters) - Germany's cabinet approved on Wednesday restrictions on the use of glyphosate, the active ingredient in Bayer's BAYGn.DE Roundup weedkiller, the agriculture ministry said on Wednesday after the EU last year authorised its use for a further ten years. "The new regulation ensures existing restrictions are legally secure," said the ministry, adding glyphosate was generally prohibited in protected water areas
B

Roche eyes return to growth after Q1 hit by forex, loss of COVID sales

UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales Background on Vabysmo in paragraph 6, on CEO from paragraph 7 By Ludwig Burger FRANKFURT, April 24 (Reuters) - Roche ROG.S confirmed ambitions to return to sales growth this year on a continued boost from eye drug Vabysmo, after first-quarter sales slipped by 6% on the loss on COVID- 19 - related revenue .
B
C
R
R

Germany's Evotec appoints Christian Wojczewski as CEO

UPDATE 1-Germany's Evotec appoints Christian Wojczewski as CEO Adds background and details throughout April 23 (Reuters) - German biotech firm Evotec EVTG.DE said on Tuesday it has appointed Christian Wojczewski as its chief executive officer, succeeding Werner Lanthaler who left after spending almost 15 years with the company. Wojczewski, whose appointment is effective July 1, has more than 20 years of experience in various management positions, most recently as CEO of Dutch healthcare company
B

Bayer Bayer Plans To Launch First Bioinsecticide For Arable Crops

BRIEF-Bayer AG - Bayer Plans To Launch First Bioinsecticide For Arable Crops April 23 (Reuters) - BAYER AG BAYGn.DE : BAYER PLANS TO LAUNCH FIRST BIOINSECTICIDE FOR ARABLE CROPS THE PRODUCT IS EXPECTED TO BE LAUNCHED IN 2028 ENTERED INTO AN AGREEMENT WITH THE BRITISH COMPANY ALPHABIO CONTROL FOR THE EXCLUSIVE LICENSE OF A NEW BIOLOGICAL INSECTICIDE
B

Bayer confirms 2024 outlook despite slow start for agriculture, consumer health units

UPDATE 1-Bayer confirms 2024 outlook despite slow start for agriculture, consumer health units Adds 2024 forecast in paragraph 3, background in paragraphs 4-5 By Ludwig Burger and Patricia Weiss FRANKFURT, April 22 (Reuters) - Bayer BAYGn.DE confirmed its full-year forecast for earnings and cash flow on Monday despite slow business at its crop science and consumer health divisions.
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.